Stockreport

INmune Bio Inc. to Introduce NeuLiv™ Program for Treatment of NASH at H.C. Wainwright 21st Annual Global Investment Conference

INmune Bio Inc. - Common stock  (INMB) 
PDF NeuLiv™ is the Third Drug Development Program From Company’s DN-TNF Platform Presentation is Scheduled for 2.10 p.m. on Sept. 9th LA JOLLA, Calif., Sept. 04, 2019 ( [Read more]